NLRP3 and diabetes mellitus: In STZ (streptozotocin)-induced hyperglycemia and hyperlipidemia in apoE −/− mice, metformin can suppress the development of diabetes-accelerated atherosclerosis and NLRP3 inflammasome activation, and this inhibitory effect can be abolished by AMPK inhibitor compound C [108].